-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Tolterodine Tartrate Extended-Release Capsules (4 mg) Have Been Approved
Category:
发布时间：2025-11-28
【概要描述】
Ringing in the charge to “forge ahead in the fourth quarter and deliver a strong finish,” Shijiazhuang Sihua Pharmaceutical Group has once again announced encouraging news: on November 28, the group’s Class 4 chemical drug—tortuosine tartrate extended-release capsules (4 mg)—received manufacturing registration approval from the National Medical Products Administration, and is deemed to have passed the bioequivalence and therapeutic equivalence evaluation for generic drugs, making it the third such product approved nationwide. To date this year, the group has secured approval for 85 new products, bringing the total to 161 drug varieties comprising 212 dosage forms that have either passed or are deemed to have passed the consistency evaluation.
Ringing in the “Final Quarter Assault: Securing a Strong Finish” call to action, Shijiazhuang Sihua Pharmaceutical Group has once again delivered encouraging news: on November 28, the group’s Class 4 chemical drug—Tolterodine Tartrate Extended-Release Capsules (4 mg)—received production registration approval from the National Medical Products Administration, and is deemed to have passed the bioequivalence and therapeutic equivalence evaluation for generic drugs, making it the third such product approved nationwide. To date this year, the group has secured approval for 85 new products, bringing the total to 161 drug varieties comprising 212 dosage forms that have either passed or are deemed to have passed the consistency evaluation.
According to available information, tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder, with symptoms including urinary urgency, urinary frequency, and urge incontinence.
Over the past two years, the Group has consistently prioritized accelerating high-quality development, steadfastly adhering to an innovation-driven development strategy. With the mission of researching, developing, and manufacturing more high-quality “Made-in-China” pharmaceuticals, the Group has continuously promoted the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, thereby powerfully catalyzing a steady stream of innovative achievements and maintaining a leading position in the industry in terms of the number of new product applications submitted and approved. These comprehensive initiatives have effectively consolidated the foundation for innovative, high-quality development, significantly enhancing the Group’s innovation influence and market competitiveness.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091